A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
SR Exenatide (PT302)
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring diabetes, exenatide, SR exenatide, Peptron
Eligibility Criteria
Inclusion Criteria:
- Healthy male subjects aged 20-45 years at screening
- Body weight over 50 kg, inclusive, and within 20% of ideal body weight
Exclusion Criteria:
- Has a present illness or medical history of hepatic, renal, respiratory, cardiovascular disease, blood tumor, mental disorder, and endocrinologic disorder, especially diabetes mellitus
- Has a sign or symptom or history related to an acute or chronic pancreatitis
- Has a known allergy or hypersensitivity to exenatide or other drugs such as aspirin, antibiotics, and so on
- Has ever been exposed to exenatide
- Shows SBP >= 150 mmHg or <= 90 mmHg or DBP >= 100 mmHg or <= 50 mmHg
- Has a presence or history of drug abuse
- Uses any prescription drug, herbal medicine within 2 weeks or OTC drugs or vitamin within 1 week prior to study drug administration
- Has been participated in other clinical trial within 2 months
- Has experience of a blood donation during 2 months or a blood transfusion during 1 month prior to study drug administration
- Heavy smoker more than 10 cigarettes/day within 3 months prior to screening
- Continuous drinker (over 21 units/week, 1 unit = 10 g of pure alcohol) or subject who can't quit drinking nor smoking during clinical trial period
- Subjects not eligible at the discretion of investigators
Sites / Locations
- Clinical Trials Center, Seoul National University Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
SR Exenatide (PT302)
Arm Description
Intervention: Drug: SR Exenatide (PT302)
Outcomes
Primary Outcome Measures
To evaluate the safety and pharmacokinetics of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection
Secondary Outcome Measures
To examine the effect on glucose control and pharmacodynamic parameters of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00964262
Brief Title
A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide
Official Title
A Dose Block-randomized, Double-blind, Placebo-controlled, Dose-escalating Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of SR Exenatide (PT302) After Subcutaneous Injection in Healthy Male Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
May 2013
Overall Recruitment Status
Completed
Study Start Date
August 2009 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
October 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Peptron, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of SR exenatide (PT302) in healthy subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
diabetes, exenatide, SR exenatide, Peptron
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
34 (Actual)
8. Arms, Groups, and Interventions
Arm Title
SR Exenatide (PT302)
Arm Type
Experimental
Arm Description
Intervention: Drug: SR Exenatide (PT302)
Intervention Type
Drug
Intervention Name(s)
SR Exenatide (PT302)
Intervention Description
0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Plcacebo of each doasage, single subcutanoeus injection
Primary Outcome Measure Information:
Title
To evaluate the safety and pharmacokinetics of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
To examine the effect on glucose control and pharmacodynamic parameters of SR exenatide (PT302) in healthy subjects after a single subcutaneous injection
Time Frame
8 weeks
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy male subjects aged 20-45 years at screening
Body weight over 50 kg, inclusive, and within 20% of ideal body weight
Exclusion Criteria:
Has a present illness or medical history of hepatic, renal, respiratory, cardiovascular disease, blood tumor, mental disorder, and endocrinologic disorder, especially diabetes mellitus
Has a sign or symptom or history related to an acute or chronic pancreatitis
Has a known allergy or hypersensitivity to exenatide or other drugs such as aspirin, antibiotics, and so on
Has ever been exposed to exenatide
Shows SBP >= 150 mmHg or <= 90 mmHg or DBP >= 100 mmHg or <= 50 mmHg
Has a presence or history of drug abuse
Uses any prescription drug, herbal medicine within 2 weeks or OTC drugs or vitamin within 1 week prior to study drug administration
Has been participated in other clinical trial within 2 months
Has experience of a blood donation during 2 months or a blood transfusion during 1 month prior to study drug administration
Heavy smoker more than 10 cigarettes/day within 3 months prior to screening
Continuous drinker (over 21 units/week, 1 unit = 10 g of pure alcohol) or subject who can't quit drinking nor smoking during clinical trial period
Subjects not eligible at the discretion of investigators
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kyung-Sang Yu, MD, PhD
Organizational Affiliation
Seoul National University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Trials Center, Seoul National University Hospital
City
Seoul
ZIP/Postal Code
110-744
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
24373998
Citation
Gu N, Cho SH, Kim J, Shin D, Seol E, Lee H, Lim KS, Shin SG, Jang IJ, Yu KS. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study. Clin Ther. 2014 Jan 1;36(1):101-14. doi: 10.1016/j.clinthera.2013.12.002. Epub 2013 Dec 27.
Results Reference
derived
Learn more about this trial
A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide
We'll reach out to this number within 24 hrs